🔬 Third-party verified peptides · Free Express Post over $200 CAD
Pantheon Peptides
Fat Loss4 cited studies

Tesamorelin

GHRH analog approved for HIV-associated visceral fat — reduces abdominal and liver fat.

SummaryMechanismDosingSafetyStudies
Research use only — not for human consumption.

What it is

Tesamorelin is a synthetic GHRH analog (Egrifta) FDA-approved for HIV-associated lipodystrophy. By restoring pulsatile GH release, it preferentially reduces visceral and hepatic fat without compromising lean mass. Off-label use in adults targets body composition, lipid profile, and aspects of metabolic health.

Mechanism of action

Stabilized GHRH(1-44) analog that binds pituitary GHRH receptors, restoring physiologic pulsatile GH and downstream IGF-1. The lipolytic effect is most pronounced on visceral and liver fat depots.

Half-life: ~26 minutes (active fragment); pulsatile GH effect lasts hours.

Evidence summary

Pivotal NEJM (2007) and JAMA (2014) trials in HIV-associated central adiposity demonstrated significant reductions in visceral adipose tissue and liver fat. Lancet HIV (2019) data show reduced fibrosis progression in NAFLD.

Typical dosing protocols

Typical dose
1000–2000 mcg
Frequency
Once daily
Cycle length
12 weeks
  • 1–2 mg subcutaneous daily, ideally morning or fasted
  • 12-week cycles common; off-label dosing varies
  • Periodic IGF-1 monitoring suggested for long-term use

Side effects & safety

  • Injection-site reactions
  • Arthralgia, mild edema, transient hyperglycemia
  • IGF-1 elevation — monitor in long cycles
Contraindications
  • • Active malignancy
  • • Pregnancy
  • • Disrupted hypothalamic-pituitary axis (e.g., recent pituitary surgery, head trauma)

Cited studies

  1. Falutz J, Allas S, Blot K, et al. (2007). Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine.
    PMID 18057338Read source ↗
  2. Stanley TL, Feldpausch MN, Oh J, et al. (2014). Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA.
    PMID 25038357Read source ↗
  3. Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV.
    PMID 31611038Read source ↗
  4. Stanley TL, Falutz J, Mamputu JC, et al. (2011). Effects of Tesamorelin on Inflammatory Markers in HIV Patients with Excess Abdominal Fat: Relationship with Visceral Adipose Reduction. AIDS.
    PMID 21422988Read source ↗
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.